Drugs / AG0302-COVID19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04993586 | Jul → Dec 2021 | COVID-19 | AnGes, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04527081 | Aug → Nov 2020 | COVID-19 | AnGes, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04655625 | Nov 2020 → Apr 2021 | COVID-19 | AnGes, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG0302-COVID19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04655625 ↗ |
| Known as | Pvax1-sars-cov2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650372 ↗ |
| Modality | Vaccine | “Study of COVID-19 DNA Vaccine (AG0302-COVID19)” NCT04527081 ↗ |
| Route | Intramuscular | “Intramuscular AG0302-COVID19 (2mg)” NCT04527081 ↗ |